A new drug, discovered and developed in the Triangle, shows promise in treating cancer.<\/p>\n\n\n\n
It\u2019s a story CBS North Carolina first reported on last year<\/strong>.<\/p>\n\n\n\nAt the time, the drug had only been tried in petri dishes and mice, but now a little girl in Philadelphia has become the first person with cancer to use the experimental drug.<\/p>\n\n\nRead More<\/span>\n\t\t<\/use>\n<\/svg>\n<\/span><\/a><\/div>\n\n<\/div>\n\n","protected":false,"raw":"\n\n\n\n\nA new drug, discovered and developed in the Triangle, shows promise in treating cancer.<\/p>\n\n\n\nIt\u2019s a story CBS North Carolina first reported on last year<\/strong>.<\/p>\n\n\n\nAt the time, the drug had only been tried in petri dishes and mice, but now a little girl in Philadelphia has become the first person with cancer to use the experimental drug.<\/p>\n\n\n\n\nRead More<\/span>\n<\/svg>\n<\/span><\/a><\/div>\n<\/div>\n"},"excerpt":{"rendered":"A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It\u2019s a story CBS North Carolina first reported on last year. At the time, the drug…<\/p>\n","protected":false},"author":239,"featured_media":12304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[31,40],"_ncst_magazine_issue":[],"class_list":["post-9000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news","tag-biomarck","tag-cancer"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"\nChild with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization\" \/>\n<meta property=\"og:description\" content=\"A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It\u2019s a story CBS North Carolina first reported on last year. At the time, the drug…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Office of Research Commercialization\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-26T12:23:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-21T01:52:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sasha Campbell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sasha Campbell\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\"},\"author\":{\"name\":\"Sasha Campbell\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"headline\":\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug\",\"datePublished\":\"2017-05-26T12:23:35+00:00\",\"dateModified\":\"2023-11-21T01:52:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\"},\"wordCount\":75,\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"keywords\":[\"Biomarck\",\"cancer\"],\"articleSection\":[\"News\",\"Startup News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\",\"name\":\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"datePublished\":\"2017-05-26T12:23:35+00:00\",\"dateModified\":\"2023-11-21T01:52:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"contentUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"width\":300,\"height\":300,\"caption\":\"startup company logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\",\"name\":\"Office of Research Commercialization\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\",\"name\":\"Sasha Campbell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"caption\":\"Sasha Campbell\"},\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/author\\\/sasha-campbell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","og_locale":"en_US","og_type":"article","og_title":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization","og_description":"A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It\u2019s a story CBS North Carolina first reported on last year. At the time, the drug…","og_url":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","og_site_name":"Office of Research Commercialization","article_published_time":"2017-05-26T12:23:35+00:00","article_modified_time":"2023-11-21T01:52:36+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","type":"image\/png"}],"author":"Sasha Campbell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sasha Campbell"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#article","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/"},"author":{"name":"Sasha Campbell","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"headline":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug","datePublished":"2017-05-26T12:23:35+00:00","dateModified":"2023-11-21T01:52:36+00:00","mainEntityOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/"},"wordCount":75,"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","keywords":["Biomarck","cancer"],"articleSection":["News","Startup News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","url":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","name":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","datePublished":"2017-05-26T12:23:35+00:00","dateModified":"2023-11-21T01:52:36+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage","url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","contentUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","width":300,"height":300,"caption":"startup company logo"},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/commercialization\/"},{"@type":"ListItem","position":2,"name":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/commercialization\/#website","url":"https:\/\/research.ncsu.edu\/commercialization\/","name":"Office of Research Commercialization","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8","name":"Sasha Campbell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","caption":"Sasha Campbell"},"url":"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/9000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/users\/239"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/comments?post=9000"}],"version-history":[{"count":2,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/9000\/revisions"}],"predecessor-version":[{"id":15201,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/9000\/revisions\/15201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media\/12304"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media?parent=9000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/categories?post=9000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/tags?post=9000"},{"taxonomy":"_ncst_magazine_issue","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/_ncst_magazine_issue?post=9000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
At the time, the drug had only been tried in petri dishes and mice, but now a little girl in Philadelphia has become the first person with cancer to use the experimental drug.<\/p>\n\n\n
It\u2019s a story CBS North Carolina first reported on last year<\/strong>.<\/p>\n\n\n\nAt the time, the drug had only been tried in petri dishes and mice, but now a little girl in Philadelphia has become the first person with cancer to use the experimental drug.<\/p>\n\n\n\n\nRead More<\/span>\n<\/svg>\n<\/span><\/a><\/div>\n<\/div>\n"},"excerpt":{"rendered":"A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It\u2019s a story CBS North Carolina first reported on last year. At the time, the drug…<\/p>\n","protected":false},"author":239,"featured_media":12304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[31,40],"_ncst_magazine_issue":[],"class_list":["post-9000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news","tag-biomarck","tag-cancer"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"\nChild with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization\" \/>\n<meta property=\"og:description\" content=\"A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It\u2019s a story CBS North Carolina first reported on last year. At the time, the drug…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Office of Research Commercialization\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-26T12:23:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-21T01:52:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sasha Campbell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sasha Campbell\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\"},\"author\":{\"name\":\"Sasha Campbell\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"headline\":\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug\",\"datePublished\":\"2017-05-26T12:23:35+00:00\",\"dateModified\":\"2023-11-21T01:52:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\"},\"wordCount\":75,\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"keywords\":[\"Biomarck\",\"cancer\"],\"articleSection\":[\"News\",\"Startup News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\",\"name\":\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"datePublished\":\"2017-05-26T12:23:35+00:00\",\"dateModified\":\"2023-11-21T01:52:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"contentUrl\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/files\\\/2018\\\/01\\\/Biomarck_Pharmaceuticals_logo.png\",\"width\":300,\"height\":300,\"caption\":\"startup company logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/2017\\\/05\\\/26\\\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#website\",\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/\",\"name\":\"Office of Research Commercialization\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/#\\\/schema\\\/person\\\/2df2b886ab8c62292fb07ec4b03d51e8\",\"name\":\"Sasha Campbell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"caption\":\"Sasha Campbell\"},\"url\":\"https:\\\/\\\/research.ncsu.edu\\\/commercialization\\\/author\\\/sasha-campbell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","og_locale":"en_US","og_type":"article","og_title":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization","og_description":"A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It\u2019s a story CBS North Carolina first reported on last year. At the time, the drug…","og_url":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","og_site_name":"Office of Research Commercialization","article_published_time":"2017-05-26T12:23:35+00:00","article_modified_time":"2023-11-21T01:52:36+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","type":"image\/png"}],"author":"Sasha Campbell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sasha Campbell"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#article","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/"},"author":{"name":"Sasha Campbell","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"headline":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug","datePublished":"2017-05-26T12:23:35+00:00","dateModified":"2023-11-21T01:52:36+00:00","mainEntityOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/"},"wordCount":75,"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","keywords":["Biomarck","cancer"],"articleSection":["News","Startup News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","url":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/","name":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals' Drug - Office of Research Commercialization","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","datePublished":"2017-05-26T12:23:35+00:00","dateModified":"2023-11-21T01:52:36+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#primaryimage","url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","contentUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2018\/01\/Biomarck_Pharmaceuticals_logo.png","width":300,"height":300,"caption":"startup company logo"},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/commercialization\/2017\/05\/26\/child-with-rare-cancer-is-first-to-receive-biomarck-pharmaceuticals-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/commercialization\/"},{"@type":"ListItem","position":2,"name":"Child with Rare Cancer is First to Receive NC State Startup Biomarck Pharmaceuticals’ Drug"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/commercialization\/#website","url":"https:\/\/research.ncsu.edu\/commercialization\/","name":"Office of Research Commercialization","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8","name":"Sasha Campbell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","caption":"Sasha Campbell"},"url":"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/9000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/users\/239"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/comments?post=9000"}],"version-history":[{"count":2,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/9000\/revisions"}],"predecessor-version":[{"id":15201,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/9000\/revisions\/15201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media\/12304"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media?parent=9000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/categories?post=9000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/tags?post=9000"},{"taxonomy":"_ncst_magazine_issue","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/_ncst_magazine_issue?post=9000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
At the time, the drug had only been tried in petri dishes and mice, but now a little girl in Philadelphia has become the first person with cancer to use the experimental drug.<\/p>\n\n\n\n
A new drug, discovered and developed in the Triangle, shows promise in treating cancer. It\u2019s a story CBS North Carolina first reported on last year. At the time, the drug…<\/p>\n","protected":false},"author":239,"featured_media":12304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[31,40],"_ncst_magazine_issue":[],"class_list":["post-9000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news","tag-biomarck","tag-cancer"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"\n